Phase II trial of paclitaxel by 24-hour continuous infusion for relapsed non-Hodgkin's lymphomas: Southwest Oncology Group Trial 9246

Journal of Clinical Oncology

Volumn 16, Issue 2, 1998, Pages 574-578

  Press, Oliver W ^a   Leblanc, Michael ^a   O'Rourke, Timothy J ^a   Gagnet, Suzanne ^a   Chapman, Robert A ^a   Balcerzak, Stanley P ^a   Fisher, Richard I ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; DEXAMETHASONE; DIPHENHYDRAMINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CARDIOTOXICITY; CLINICAL TRIAL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; FATIGUE; FEMALE; GRANULOCYTOPENIA; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; THROMBOCYTOPENIA;

EID: 0031891979     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.2.574     Document Type: Article

References (11)

1. Horning SJ: Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20:75-88, 1993
2. Fisher RI, Gaynor ER, Dahlberg S, et al: Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 328:1002-1006, 1993
3. Rowinsky EK, Donehower RC: Paclitaxel (TAXOL). N Engl J Med 332:1004-1014, 1995
4. Hortobagyi GN, Holmes FA: Single-agent paclitaxel for the treatment of breast cancer: An overview. Semin Oncol 23:4-9, 1996
5. Caldas C, McGuire WP III: Paclitaxel (TAXOL) therapy in ovarian carcinoma. Semin Oncol 20:50-55, 1993
6. Wilson WH, Chabner BA, Bryant G, et al: Phase II study of paclitaxel in relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:381-386, 1995
7. Younes A, Sarris A, Melnyk A, et al: Three-hour paclitaxel infusion in patients with refractory and relapsed non-Hodgkin's lymphomas. J Clin Oncol 13:584-587, 1995
8. Non-Hodgkin's Lymphoma Pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: Summary and description of a working formulation for clinical usage. Cancer 49:2112-2135, 1982
9. The International Non-Hodgkin's Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329:987-994, 1993
10. Younes A, Ayoub J-P, Hagemeister, et al: No effect of 96-hour paclitaxel infusion in patients with relapsed non-Hodgkin's lymphoma refractory to a 3-hour infusion schedule. J Clin Oncol 14:543-548, 1996
11. Sarris A, Younes A, McLaughlin P, et al: Cyclosporin A does not reverse clinical resistance to paclitaxel in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 14:233-239, 1996